Jennison Associates LLC Makes New Investment in Upstream Bio, Inc. $UPB

Key Points

• Jennison Associates bought a new position of 288,847 shares in Upstream Bio (~$7.84M), representing 0.53% ownership at quarter-end, while other institutions—most notably UBS (1,806,243 shares, ~$49.0M), Pictet, Marshall Wace and Vanguard—also materially increased or initiated stakes.
• Analyst sentiment is mixed: MarketBeat shows a consensus of Moderate Buy with an average price target of $39, but recent downgrades from Evercore and Wall Street Zen have trimmed optimism.
• Financials and price action remain weak—Upstream Bio reported a ($0.79) EPS miss with $0.67M revenue, very negative margins/ROE, and trades around $9.40 (1‑year range $7.25–$33.68) with a market cap of about $511.6M.

Jennison Associates LLC acquired a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 288,847 shares of the company's stock, valued at approximately $7,842,000. Jennison Associates LLC owned 0.53% of Upstream Bio at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of UPB. UBS Group AG lifted its position in shares of Upstream Bio by 563.4% in the 4th quarter. UBS Group AG now owns 1,806,243 shares of the company's stock worth $49,039,000 after acquiring an additional 1,533,972 shares during the period. Pictet Asset Management Holding SA bought a new stake in shares of Upstream Bio in the 4th quarter worth approximately $20,991,000. Marshall Wace LLP lifted its position in shares of Upstream Bio by 198.8% in the 3rd quarter. Marshall Wace LLP now owns 867,999 shares of the company's stock worth $16,327,000 after acquiring an additional 577,473 shares during the period. Integral Health Asset Management LLC bought a new stake in shares of Upstream Bio in the 3rd quarter worth approximately $10,816,000. Finally, Vanguard Group Inc. lifted its position in shares of Upstream Bio by 12.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,442,551 shares of the company's stock worth $45,944,000 after acquiring an additional 271,718 shares during the period.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Evercore downgraded Upstream Bio from an "outperform" rating to an "in-line" rating and set a $15.00 price objective for the company. in a research report on Friday, March 27th. Wall Street Zen downgraded Upstream Bio from a "hold" rating to a "sell" rating in a research report on Saturday, March 28th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Upstream Bio in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $39.00.

Upstream Bio Price Performance

Upstream Bio stock opened at $9.40 on Friday. The company has a market capitalization of $511.55 million, a PE ratio of -3.52 and a beta of 1.29. Upstream Bio, Inc. has a one year low of $7.25 and a one year high of $33.68. The business has a 50 day simple moving average of $9.03 and a 200 day simple moving average of $20.00.

Upstream Bio (NASDAQ:UPB - Get Free Report) last posted its earnings results on Thursday, March 26th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.06). The company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.52 million. Upstream Bio had a negative return on equity of 36.48% and a negative net margin of 5,026.03%. Equities analysts anticipate that Upstream Bio, Inc. will post -3.02 earnings per share for the current fiscal year.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio's approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company's research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.